CPT code 81225 covers targeted molecular testing for common variants in the CYP2C19 gene, a pharmacogenomic marker that influences metabolism of several commonly prescribed medications. Nationally, CYP2C19 testing supports personalized prescribing and can affect medication selection and dosing for drugs such as certain antiplatelet agents and psychotropics, making the code relevant to payers, laboratories, and clinicians engaged in precision medicine initiatives. Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise clinical context for the test, payer coverage framing, and the types of operational benchmarks and policy updates typically associated with molecular diagnostic billing. The publication outlines how CPT code 81225 is used to report targeted CYP2C19 genotyping performed in clinical laboratories, common sites of service, and the programmatic considerations payers and providers monitor for pharmacogenomic testing. Where available, the analysis highlights reimbursement patterns, documentation and lab reporting expectations, and implications for laboratory workflow and claims processing. Data not available in the input is noted where specific payer policies or taxonomies are required.